The work of SymBio Pharmaceuticals capitalizes on existing cutting-edge research and technologies in order to spur the clinical development and launch of sought after drug therapies in Japan.
Prominent clinical physicians and scientists, with track records of success and a wealth of experience in wide-ranging disciplines related to drug development, serve as advisors at SymBio. Together, the SAB and Senior Advisors render crucial decisions on SymBio's next drug targets and definitive steps to be taken, with the underlying goal of addressing Enderserved medical needs' in Japan and other Asia-Pacific countries such as China, Korea, Taiwan and Singapore.
“The therapeutic gains generated from advances being made in medical treatments should be made available to all patients suffering from rare or difficult-to-treat diseases, and I am convinced that SymBio's efforts in drug development will help realize this greater accessibility to much-needed medicines for all patients.”
Chair: George Morstyn, M.D., Ph.D.
Former Senior Vice-President of Development and CMO, Amgen Inc.
Currently chief executive officer of G & R Morstyn Pty Ltd.,
“I share the unique patient-oriented vision of helping those who suffer from difficult-to-treat diseases, and I am therefore fully supportive of SymBio's endeavor.”
Robert Lewis, M.D., Ph.D.
Former Senior Vice-President of US R&D, Aventis Pharmaceuticals;
Chief Scientific Officer, Cell Therapeutics; Head of Discovery Research,
Syntex Pharmaceuticals; Associate Professor, Harvard Medical School
Currently serves as consultant in Immunology/Inflammation, Roche Palo Alto;
Adjunct Faculty Member, Rockefeller University, New York
“SymBio's vision which thrives on new challenges, I believe, will help to advance pharmaceutical innovation and make medicine become more viable and progressive.”
Tomomitsu Hotta, M.D.
Honorary President, National Cancer Center
Honorary Director, NHO Nagoya Medical Center
“Drug development for rare cancers is difficult.
SymBio supports contributions to new drug development in these challenging fields.”
Makoto Ogawa, M.D., Ph.D.
Honorary President, Aichi Cancer Center
“We support the philosophy of "Delivering Hope to Patients in Need." We would like to co-develop new treatment methods for orphan illnesses which other larger pharmaceutical companies choose not to get involved with.”
Tatsutoshi Nakahata, M.D., Ph.D.
Adviser and Professor, Center for iPS Cell Research and Application (CiRA),
Head of Drug Discovery Technology Development Office
“In a world where market principles are entrenched, the philosophy of adhering to medical basics in addressing the suffering of patients resonates with us all, and I sincerely wish to help.”
Toshio Suda, M.D., Ph.D.
Professor, International Research Center for Medical Sciences, Kumamoto University
Professor, Cancer Science Institute of Singapore, National University of Singapore
“SymBio is a unique drug discovery firm originating from creative collaboration. We anticipate incredible results that will truly address the needs of patients.”
Tsutomu Takeuchi, M.D., Ph.D.
Vice-President, Keio University
Professor of Medicine, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
"The SymBio vision of teamwork and establishing a symbiotic relationship between physicians, scientists, regulatory agencies, investors and patients resonates strongly within me. We're working to establish therapeutic alternatives for patients who are currently suffering from rare or therapeutically-challenging diseases."
Toshio Heike, M.D., Ph.D.
Director of Hyogo Prefectural Amagasaki General Medical Center
"I offer an unreserved support to the mission of SymBio which aims to help patients suffering from rare diseases through innovative drug development"
Koichi Takahashi, MD
Assistant Professor, Department of Leukemia and Genomic Medicine, The University of Texas MD Anderson Cancer Center
Mathias J. Rummel, M.D., Ph.D.
Medical Director Clinic for Hematology
and Medical Oncology Justus-Liebig-University